CBR1 (carbonyl reductase 1) may reduce the effect of many anti-cancer drugs by metabolization, such as reducing the effect of doxorubicin in breast cancer patients [40] and attenuating the effect of arsenic trioxide in leukemia patients [41]. The gene discussed is CBR1; the disease is breast carcinoma.